Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.

Although transgene-based reporter gene assays have been used to discover small molecules targeting expression of cancer-driving genes, the success is limited due to the fact that reporter gene expression regulated by incomplete cis-acting elements and foreign epigenetic environments does not faithfully reproduce chemical responses of endogenous genes. Here, we present an internal ribosome entry site-based strategy for bicistronically co-expressing reporter genes with an endogenous gene in the native gene locus, yielding an in situ reporter assay closely mimicking endogenous gene expression without disintegrating its function. This strategy combines the CRISPR-Cas9-mediated genome-editing tool with the recombinase-mediated cassette-exchange technology, and allows for rapid development of orthogonal assays for excluding false hits generated from primary screens. We validated this strategy by developing a screening platform for identifying compounds targeting oncogenic eIF4E, and demonstrated that the novel reporter assays are powerful in searching for transcription-targeted lead compounds with high confidence.

[1]  Claire Halpin,et al.  E unum pluribus: multiple proteins from a self-processing polyprotein. , 2006, Trends in biotechnology.

[2]  A. Bogdanove,et al.  TAL Effectors: Customizable Proteins for DNA Targeting , 2011, Science.

[3]  R. Guha,et al.  Genome Editing-Enabled HTS Assays Expand Drug Target Pathways for Charcot–Marie–Tooth Disease , 2014, ACS chemical biology.

[4]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[5]  F. Marks,et al.  Rottlerin, a novel protein kinase inhibitor. , 1994, Biochemical and biophysical research communications.

[6]  Rick Gussio,et al.  Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. , 2003, Biochemical and biophysical research communications.

[7]  James Inglese,et al.  A coincidence reporter-gene system for high-throughput screening , 2012, Nature Methods.

[8]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[9]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[10]  Robert Tjian,et al.  Looping Back to Leap Forward: Transcription Enters a New Era , 2014, Cell.

[11]  G. Bejerano,et al.  Enhancers: five essential questions , 2013, Nature Reviews Genetics.

[12]  Hongbo Wang,et al.  A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. , 2011, Neoplasia.

[13]  B. Aggarwal,et al.  A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NFκB motif drives the transition from a repressed to an activated state of gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[15]  D. Auld,et al.  Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. , 2010, Chemistry & biology.

[16]  J. Graff,et al.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.

[17]  T. Schlake,et al.  Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. , 1994, Biochemistry.

[18]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[19]  Christopher P Austin,et al.  Characterization of chemical libraries for luciferase inhibitory activity. , 2008, Journal of medicinal chemistry.

[20]  Zhengxin Wang,et al.  A Novel High-Throughput Screening System Identifies a Small Molecule Repressive for Matrix Metalloproteinase-9 Expression , 2008, Molecular Pharmacology.

[21]  P. Pognonec,et al.  A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli , 2006, BMC biotechnology.

[22]  Gang Liu,et al.  An RNA-zipcode-independent mechanism that localizes Dia1 mRNA to the perinuclear ER through interactions between Dia1 nascent peptide and Rho–GTP , 2011, Journal of Cell Science.

[23]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[24]  V. Polunovsky,et al.  Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation , 2012, Molecular Cancer Therapeutics.

[25]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[26]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[27]  D. Russell,et al.  AAV-mediated gene targeting methods for human cells , 2011, Nature Protocols.

[28]  P. Higgins,et al.  Drugging the undruggable: transcription therapy for cancer. , 2013, Biochimica et biophysica acta.

[29]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[30]  Douglas D. Boyd,et al.  Histone H3 Acetylation and H3 K4 Methylation Define Distinct Chromatin Regions Permissive for Transgene Expression , 2006, Molecular and Cellular Biology.

[31]  William Arbuthnot Sir Lane,et al.  Epitope tagging of endogenous genes in diverse human cell lines , 2008, Nucleic acids research.

[32]  P. Workman,et al.  Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. , 2005, Cancer research.

[33]  J. Bode,et al.  Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. , 2001, Current opinion in biotechnology.

[34]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[35]  A. Hsieh,et al.  Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer , 2010, Clinical Cancer Research.

[36]  Peter G Schultz,et al.  Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 , 2009, Proceedings of the National Academy of Sciences.

[37]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[38]  John K. Buolamwini,et al.  A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis , 2010, Molecular Cancer Therapeutics.

[39]  William Arbuthnot Sir Lane,et al.  Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. , 2006, Chemistry & biology.